Research links aspirin and cancer success - don't start tablets yet

A new research has found that taking low-dose aspirin could reduce risk of cancer. This study has been published within the Lancet. The research re-reviewed eight studies that included over 25,000 participants. There are nevertheless major spaces in this study. You shouldn't immediately begin taking aspirin, but talk with your doctor.

Less possibility of cancer with aspirin

The meta-study published today was completed by a team of British researchers. The risk of dying from cancer goes down when taking 75 milligrams of aspirin regular for five or more years. Deaths from lung and prostate cancer were reduced about 20 percent, gastrointestinal cancers by 54 percent and esophageal cancers by 60 percent. Between 5 and 20 years were the regular low-dose aspirin taken. The cardiovascular effects while taking regular aspirin was the original purpose of the research.

Not suggesting day-to-day aspirin

Researchers do not suggest that you take aspirin day-to-day even though there was a lot of improvement on surviving cancers with it. ”Proof of principle” needs to be found with more studies. Also, the meta-study only had a few subjects in it. Thinning of blood, heartburn, loss of balance and ringing in the ears can all be brought on by aspirin although it is considered relatively safe. "I certainly think we wouldn't want for making any treatment decisions depending on this research," said Dr. Raymond DuBois, a provost of the University of Texas M.D. Anderson Cancer Center.

Difficulties to look at first with aspirin-cancer research

The 2 studies that found the link between aspirin and improved cancer success rates have both been conducted by the very same group of researchers in Britain. You will find many spaces that need to be looked at in the studies. Only 33 percent were women in the main meta-analysis. That is out of 25,000 subjects. Additionally, data was absent on the impact of taking low-dose aspirin on less-common cancers, such as brain and stomach cancer. The group of patients may be statistically skewed since the benefit of aspirin on the heart was what the studies were at first working on.

It is not smart to begin taking aspirin as there is not enough research on the subject yet although it might be really exciting to begin exploring the use of aspirin on cancer.

Articles cited

Washington Post

Business Week